News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
3SBIO Skyrockets 30%+ as It Grants Exclusive License to Pfizer, Issues US$100M Worth of New Shrs
3SBIO (01530.HK) opened 14.9% higher at a peak of $22 this morning, and last skyrocketed 31.03% to $19, with 44.33 million shares traded, involving $834 million.3SBIO announced the...
Reset
Send
The window will close in 5 seconds
3SBIO Skyrockets 30%+ as It Grants Exclusive License to Pfizer, Issues US$100M Worth of New Shrs
Close
Recommend
6
Positive
14
Negative
17
 
SHORT SELL
 
STOCK INFO

3SBIO (01530.HK)  +1.770 (+9.228%)    Short selling $244.10M; Ratio 14.790%   opened 14.9% higher at a peak of $22 this morning, and last skyrocketed 31.03% to $19, with 44.33 million shares traded, involving $834 million.

3SBIO announced the signing of an exclusive licensing agreement with Pfizer (PFE.US)      , granting Pfizer an exclusive license to develop, manufacture and commercialize its product, PD-1/VEGF bispecific antibody (SSGJ-707), worldwide excluding mainland China, with a combined upfront payment and potential milestone of up to US$6.05 billion.

Related NewsCiti Elevates 3SBIO's TP to HKD21 on Co-op on SSGJ-707 w/ Pfizer
In addition, Pfizer intended to spend US$100 million to subscribe for new shares to be allotted by 3SBIO.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-21 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AAStocks Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.